Seaport Therapeutics, Inc. Common Stock (SPTX) Stock

About Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Seaport Therapeutics, Inc. Common Stock is led by CEO Daphne Zohar, employs 58 people, headquartered in US, publicly traded since 2026.

Seaport Therapeutics, Inc. Common Stock (SPTX) stock trades at $23.02 with a market capitalization of $1.23B. The stock is valued at a price-to-earnings (P/E) ratio of -13.95, price-to-book of 2.92, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $14.85 and $24.48, and currently trades 6.0% below its 52-week high.

On profitability, Seaport Therapeutics, Inc. Common Stock generates a return on equity (ROE) of -57.34%, return on capital employed of -21.91%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.seaporttx.com